GSK Gets Patent Cut From Wellbutrin Antitrust Action

Law360, New York (September 15, 2010, 12:06 PM EDT) -- GlaxoSmithKline PLC has won a bid to purge all claims related to one patent in a putative class action brought by employee benefit plans that accuses the drugmaker of filing baseless infringement suits in an effort to delay generic competition for the antidepressant Wellbutrin SR.

Judge Lawrence Stengel of the U.S. District Court for the Eastern District of Pennsylvania on Monday denied GSK's motion for summary judgment as to all of the indirect purchasers' claims, but granted the pharmaceutical giant's motion to dismiss claims regarding U.S....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.